<DOC>
	<DOCNO>NCT00080639</DOCNO>
	<brief_summary>RATIONALE : Measuring level CA 125 blood sample woman high risk develop ovarian cancer may help doctor detect cancer early plan effective treatment . PURPOSE : This phase II trial study CA-125 level screen cancer woman high risk develop ovarian cancer .</brief_summary>
	<brief_title>CA-125 Screening Patients High Risk Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility prospective screening ovarian cancer high-risk patient . - Determine normal range distribution CA 125 within patient ( subclassification menopausal status , estrogen replacement therapy usage , prophylactic oophorectomy ) . Secondary - Determine estimate specificity positive predictive value risk cancer algorithm suitable design definitive trial screen ovarian cancer patient . OUTLINE : This multicenter , pilot study . Patients undergo blood collection CA 125 level measure baseline every 3 month 1-2 year . Patients may refer ovarian ultrasound indicate CA 125 result . Patients follow 6 month annually thereafter . PROJECTED ACCRUAL : A total 2,400 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk develop ovarian cancer , determine meeting criterion 1 follow : Family history least 2 ovarian breast* cancer among patient first seconddegree relative within lineage** If breast cancer* require meet criterion , least 1 breast cancer* must premenopausal ( diagnose age 50 menopausal status unknown ) NOTE : **Multiple primary cancer person satisfies criterion Ashkenazi Jewish ethnicity meet criteria 1 following : Prior breast cancer* diagnosis One firstdegree 2 seconddegree relative breast* ovarian cancer If breast cancer require meet criterion , least 1 breast cancer* must premenopausal ( diagnose age 50 menopausal status unknown ) Probability BRCA1 BRCA2 mutation great 20 % , determine BRCAPRO 95 % posterior probability interval This criterion include follow situation BRCAPRO require : Tested positive BRCA1 BRCA2 mutation ( 100 % probability ) First seconddegree relative BRCA1 BRCA2 mutation NOTE : *Including ductal carcinoma situ No ovarian cancer , include low malignant potential cancer primary papillary serous carcinoma peritoneum PATIENT CHARACTERISTICS : Age 30 Performance status Not specify Life expectancy Not specify Hematopoietic No hemophilia No bleeding disorder Hepatic Not specify Renal Not specify Pulmonary No emphysema Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No psychiatric psychological condition would preclude give informed consent No concurrent untreated malignancy except nonmelanoma skin cancer No medical condition would preclude blood draw ( e.g. , chronic infectious disease ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 month since prior adjuvant chemotherapy cancer Endocrine therapy Concurrent adjuvant hormonal therapy ( e.g. , tamoxifen , leuprolide , goserelin ) allow Radiotherapy More 3 month since prior adjuvant radiotherapy cancer Surgery More 3 month since prior intraperitoneal surgery ( laparoscopy laparotomy ) Prior prophylactic oophorectomy allow Other More 5 year since prior treatment ( exclude hormonal therapy ) metastatic malignancy No concurrent participation ovarian cancer early detection trial</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ovarian epithelial cancer</keyword>
</DOC>